Filtered By:
Cancer: Myeloma

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 122 results found since Jan 2013.

Effective Lipidoid Nanoparticle Delivery In Vivo of siRNA Targeting Kappa Light Chain Production in a Murine Xenograft Model
CONCLUSIONS: We have previously shown that siIGKC, a pool of siRNA directed at consensus sequences in the LC constant region gene, can significantly reduce LC production in clonal plasma cells from patients, in human myeloma cell lines, and in vivo in a flank plasmacytoma xenograft model. In this work, we show that 8B-3 is a promising LPN for delivery of siRNA to human plasma cells and, when loaded with siIGKC, can with relative safety significantly reduce circulating LC in the NSG JJN3 IP model after 3 daily IP injections despite rapid tumor growth. We also show the utility of the NSG JJN3 IP model for the study of LC dir...
Source: Blood - November 21, 2018 Category: Hematology Authors: Ma, X., Zhou, P., Kugelmass, A., Toskic, D., Warner, M., Lee, L. X., Fogaren, T., Wang, M., Li, Y., Yang, L., Xu, Q., Comenzo, R. Tags: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II Source Type: research

One siRNA pool targeting the {lambda} constant region stops {lambda} light-chain production and causes terminal endoplasmic reticulum stress
In systemic light-chain amyloidosis, light chains produced by clonal plasma cells cause organ damage and early death. In pursuit of novel therapy, we developed 1 pool of short interfering RNA (siRNA) targeting the constant region of light chains that substantially and promptly reduces -light-chain production and secretion by human plasma cells regardless of sequence diversity. In clones producing intact immunoglobulin G (IgG) antibodies (containing paired heavy and light chains), the secretion of intact antibodies is reduced, and all 3 branches of the unfolded protein response are activated by accumulation of unpaired IgG ...
Source: Blood - May 29, 2014 Category: Hematology Authors: Zhou, P., Ma, X., Iyer, L., Chaulagain, C., Comenzo, R. L. Tags: Multiple Myeloma, Lymphoid Neoplasia Source Type: research

Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells
maagacli
Source: Cancer Gene Therapy - June 6, 2014 Category: Cancer & Oncology Authors: M KoldehoffD W BeelenA H Elmaagacli Source Type: research

Cancers, Vol. 14, Pages 566: Successful Incorporation of Exosome-Capturing Antibody-siRNA Complexes into Multiple Myeloma Cells and Suppression of Targeted mRNA Transcripts
In conclusion, exosome-capturing Ab-conjugated siRNAs with branched Arg linkers can be effectively delivered into MM cells via uptake of exosomes by parental cells. This technology has the potential to lead to a breakthrough in drug delivery systems for hematologic cancers.
Source: Cancers - January 23, 2022 Category: Cancer & Oncology Authors: Emi Soma Asako Yamayoshi Yuki Toda Yuji Mishima Shigekuni Hosogi Eishi Ashihara Tags: Article Source Type: research

Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling
In this study, we aimed to investigate the potential anti-proliferative and pro-apoptotic activities of SNG in a panel of MM cell lines (U266, IM9, MM1S, and RPMI-8226). SNG treatment of MM cells resulted in a dose-dependent decrease in cell viability through mitochondrial membrane potential loss and activation of caspase 3, 9, and cleavage of PARP. Pre-treatment of MM cells with a universal caspase inhibitor, Z-VAD-FMK, prevented SNG mediated loss of cell viability, apoptosis, and caspase activation, confirming that SNG-mediated apoptosis is caspase-dependent. The SNG-mediated apoptosis appears to be resulted from suppres...
Source: Frontiers in Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma.
CONCLUSION: DKK1 is closely related to the pathogenesis and prognosis of human MM, which might be a potential biomarker for the diagnosis of MM. PMID: 30614800 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - January 8, 2019 Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research

PGC1 β Regulates Breast Tumor Growth and Metastasis by SREBP1-Mediated HKDC1 Expression
Conclusions: PGC1β regulates breast cancer tumor growth and metastasis by SREBP1-mediated HKDC1 expression. This provides a novel therapeutic strategy through targeting the PGC1β/HKDC1 signaling pathway for breast cancer treatment. Introduction Breast cancer is a very common cancer with significant premature mortality in women. Around 12% of women in USA will have chance to be diagnosed with breast cancer during their lifetimes (1, 2). The development of breast cancer is regulated by many factors, and even as average survival rates have increased significantly as a result of many advanced treatments...
Source: Frontiers in Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Binding of B‐cell maturation antigen to B‐cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways
In this study, we characterized the mechanism underlying the protein kinase B (Akt) and c‐Jun N‐terminal kinase (JNK) pathways and BCMA interactions in regulating multiple myeloma (MM) cell survival. It was found that the expression levels of B cell‐activating factor (BAFF) and BCMA were increased in MM cells as compared with those in normal controls. The proliferation of U266 cells was induced by recombinant human BAFF (rhBAFF) and could also be decreased by BCMA siRNA. The expression of Bcl‐2 protein was up‐regulated, and Bax protein was down‐regulated after rhBAFF treatment, which could be reversed by BCMA s...
Source: Cell Biochemistry and Function - January 1, 2016 Category: Biochemistry Authors: Xianjuan Shen, Yuehua Guo, Jing Qi, Wei Shi, Xinhua Wu, Shaoqing Ju Tags: Research Article Source Type: research

Chidamide, a Novel Histone Deacetylase Inhibitor, Inhibits Multiple Myeloma Cells Proliferation through Succinate Dehydrogenase Subunit a
Most patients with multiple myeloma (MM) would finally relapse. Current chemotherapy regimens have limited effect on relapse MM patients. As a new histone deacetylase inhibitor, chidamide has been used in malignancy treatment such as peripheral T-cell lymphoma. However, it is still unknown if chidamide can be used in MM.To determine the target gene of chidamide in MM patients, we performed RNA-Seq analysis using 3 MM patients' bone marrow mononuclear cells. Their BMMCs were cultured with 6μM chidamide or not, and six of the most significantly changed coding genes were selected. Realtime RT-PCR showed that compared with ...
Source: Blood - November 21, 2018 Category: Hematology Authors: Sun, Y., Liu, P., Li, J. Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research

MT2-MMP is differentially expressed in multiple myeloma cells and mediates their growth and progression
Cell Signal. 2022 Jan 15:110248. doi: 10.1016/j.cellsig.2022.110248. Online ahead of print.ABSTRACTOBJECTIVE: Membrane type-matrix metalloproteinases (MT-MMPs) are known as key regulators of cancer progression/metastasis. However, their roles in the growth and progression of multiple myeloma (MM) have not been yet elucidated.METHODS AND MATERIALS: The expression of 6 MT-MMPs in MM, B cell lines, and normal peripheral blood (PB) cells were measured by RT-PCR, qRT-PCR, flow cytometry, western blotting, and immunocytochemistry. B lymphocytes, CD19-/CD138-, and CD19-/CD138+ cells, known as malignant plasma cells (MPC), were so...
Source: Cellular Signalling - January 18, 2022 Category: Cytology Authors: Shohreh Fakhari Ali Jalili Bahram Nikkhoo Bayazid Ghaderi Mohammad Amin Boshagh Sako Mirzaie Mohammad Moradzad Source Type: research

Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration
Conclusions: Providing first evidence of a cell biological function of CT45, we suggest that this cancer/testis antigen is involved in the modulation of cell morphology, cell adherence and cell motility. Enhanced motility and/or invasiveness of CT45-positive cells could contribute to the more severe disease progression that is correlated to CT45-positivity in several malignancies.
Source: Cell Communication and Signaling - June 10, 2013 Category: Molecular Biology Authors: Anja KoopNadia SellamiSabine Adam-KlagesMarcus LettauDieter KabelitzOttmar JanssenHans-Jürgen Heidebrecht Source Type: research

HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
CONCLUSIONS: The HIF-1α protein in MMECs may induce angiogenesis and resistance to bortezomib and lenalidomide and be a plausible target for the antiangiogenic management of well defined relapsed/refractory MM patients. It may also have prognostic significance. PMID: 24297864 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 2, 2013 Category: Cancer & Oncology Authors: Ria R, Catacchio I, Berardi S, De Luisi A, Caivano A, Piccoli C, Ruggieri V, Frassanito MA, Ribatti D, Nico B, Annese T, Ruggieri S, Guarini A, Minoia C, Ditonno P, Angelucci E, Derudas D, Moschetta M, Dammacco F, Vacca A Tags: Clin Cancer Res Source Type: research

Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
Conclusion: Downregulation of beta5i subunit expression is a major determinant in acquisition of bortezomib-resistance and enhancement of its proteasomal assembly after induction by interferon-gamma facilitates restoration of sensitivity in bortezomib-resistant leukemia cells towards bortezomib and next generation (immuno) proteasome inhibitors.
Source: Journal of Hematology and Oncology - January 13, 2014 Category: Hematology Authors: Denise NiewerthGertjan KaspersYehuda AssarafJohan van MeerlooChristopher KirkJanet AnderlJonathan BlankPeter van de VenSonja ZweegmanGerrit JansenJacqueline Cloos Source Type: research